Phase 3,Single Arm,Open-Label Study Evaluating Ovarian Suppression Following 3 Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination With Endocrine Therapy in Premenopausal Subjects With Hormone-Receptor-Positive (HR+),Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer

Date Added
February 16th, 2022
PRO Number
Gilbert Bader

List of Studies

Cancer, Cancer/Breast, Drug Studies, Men's Health, Women's Health

This study is for subjects that have been diagnosed with HR+, HER2-negative breast cancer while still being in a premenopausal hormone status (i.e. females with active ovaries that produce hormones that cause menstrual cycles (even if they are not regular). The investigational drug that will be used is TOL2506. The drug will be given as an injection. The study is to assess suppression of ovarian function
following administration of TOL2506 in premenopausal subjects with HR+, HER2-negative breast cancer. Participants can expect to be in this study for 24 months.

Recruitment Contact
HCC Clinical Trials Office

-- OR --